Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week
Browsing Category

Biotech

Biotech

Group By Ticker
Sort By
Newest | Oldest
Read More
3 minute read
  • Biotech
  • FDA
  • General
  • News

Nevro Late Wednesday Announces FDA Approval Of HFX iQ Spinal Cord Stimulation System To Personalize The Treatment of Chronic Pain

By Benzinga Newsdesk
October 13, 1:08 AM
Next Generation Senza® HFX iQ™ is the First and Only SCS System that Uses Artificial Intelligence to Optimize and Maintain Pain Relief Using Each Patient's Response REDWOOD CITY, Calif., Oct. 12,

NVRO

Read More
1 minute read
  • After-Hours Center
  • Biotech
  • General
  • Movers
  • News
  • Penny Stocks
  • Small Cap
  • Trading Ideas

What Happened With Ocugen Shares During Wednesday’s After-Hours Session

By Henry Khederian
October 12, 9:44 PM
Ocugen Inc (NASDAQ: OCGN) shares traded marginally higher by 1.22% at $1.66 during Wednesday's after-hours session.

OCGN

Read More
2 minute read
  • Biotech
  • General
  • Health Care
  • Movers
  • Top Stories
  • Trading Ideas

Moderna Rallies On Merck Collaboration: Can Drugmaker Replace COVID Vaccine Revenue?

By Joel Elconin
October 12, 5:22 PM
In late 2020, when the world was searching for a vaccine or cure for COVID-19, the price action in Moderna Inc (NASDAQ: MRNA) was discussed frequently on Benzinga's PreMarket Prep show. 

MRK

Read More
1 minute read
  • Biotech
  • FDA
  • General
  • Health Care
  • Movers
  • News
  • Penny Stocks
  • Trading Ideas

Why Evofem Biosciences Shares Are Plunging Today?

By Vandana Singh
October 12, 2:17 PM
Evofem Biosciences Inc's (OTC: EVFM) recently completed the Phase 3 EVOGUARD trial evaluating Phexxi vaginal gel (EVO100) to prevent chlamydia and gonorrhea infection in women but did not achieve its endpoints.

EVFM

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • M&A
  • News

Bankrupt Zosano Sells Its Drug Delivery Tech That Once Partnered With Pharma Giants

By Vandana Singh
October 12, 11:47 AM
Emergex Vaccines Holding Limited acquired the assets of Zosano Pharma Corporation. The sale was part of the customary proceedings after…

LLY

Read More
2 minute read
  • Biotech
  • FDA
  • General
  • News

Cassava Sciences Has Initiated And Started Enrollment For A New Open Label Extension To Their Phase 3 Trial Of Simufilam For The Treatment Of Alzheimer’s Disease

By Benzinga Newsdesk
October 12, 11:31 AM
Open-label Extension for Phase 3 Clinical Trials of Simufilam - Full Text View - ClinicalTrials.gov Brief Summary: The goal of this open-label extension study is to assess long-term safety and tolerability of simufilam

SAVA

Read More
1 minute read
  • Biotech
  • Contracts
  • General
  • Health Care
  • Large Cap
  • Movers
  • News
  • Penny Stocks
  • Trading Ideas

Moderna In-Licenses Autolus’ Technology For mRNA-Based Cancer Therapeutics

By Vandana Singh
October 12, 11:30 AM
Moderna Inc (NASDAQ:MRNA) has exercised its option to license Autolus Therapeutics plc’s (NASDAQ:AUTL) proprietary binders against an undisclosed immuno-oncology target for…

AUTL

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • Large Cap
  • Movers
  • News
  • Trading Ideas

Yet Another Good News For Moderna, FDA Approves Its New Omicron Adapted COVID-19 Shot

By Vandana Singh
October 12, 11:21 AM
Moderna Inc (NASDAQ:MRNA) has received FDA emergency use authorization (EUA) for its BA.4/BA.5 Omicron-targeting bivalent COVID-19 booster vaccine, mRNA-1273.222, in children…

MRK

Read More
2 minute read
  • Biotech
  • FDA
  • General
  • News

COMPASS Pathways Announces Phase 3 Pivotal Program Design For COMP360 Psilocybin In Treatment Resistant Depression At Capital Markets Day

By Benzinga Newsdesk
October 12, 11:10 AM
COMPASS Pathways plc (NASDAQ:CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the Phase 3 pivotal program design for COMP360

CMPS

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • News
  • Small Cap

Novavax Prototype COVID-19 Vaccine Data Shows Benefit Against Variants

By Vandana Singh
October 12, 10:50 AM
Novavax Inc (NASDAQ: NVAX) presented data from the Phase 3 PREVENT-19 trial and Study 307 (Lot Consistency) at the World Vaccine Congress Europe 2022. 

NVAX

Posts pagination

Previous 1 … 661 662 663 … 795 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service